Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives.
BRCA 1/2
PARP inhibitors
anti-angiogenics
front-line maintenance therapy
homologous recombination deficiency
immunotherapy
ovarian cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Aug 2020
25 Aug 2020
Historique:
received:
21
07
2020
revised:
19
08
2020
accepted:
21
08
2020
entrez:
29
8
2020
pubmed:
29
8
2020
medline:
29
8
2020
Statut:
epublish
Résumé
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic
Identifiants
pubmed: 32854393
pii: cancers12092414
doi: 10.3390/cancers12092414
pmc: PMC7564452
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Breast Cancer Res. 2014 Jun 03;16(3):211
pubmed: 25093514
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
JNCI Cancer Spectr. 2020 Apr 04;4(3):pkaa026
pubmed: 32596636
Br J Cancer. 2018 Nov;119(11):1401-1409
pubmed: 30353044
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Bull Cancer. 2017 May;104 Suppl 1:S6-S15
pubmed: 28625315
J Pharm Sci. 2014 Jun;103(6):1913-20
pubmed: 24700236
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Mol Cancer Res. 2018 Feb;16(2):222-232
pubmed: 29133592
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6
pubmed: 24085845
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Mol Cancer Ther. 2015 Oct;14(10):2321-31
pubmed: 26294743
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Mol Cancer Res. 2018 Jul;16(7):1103-1111
pubmed: 29724815
Pharmacol Res. 2018 Nov;137:104-113
pubmed: 30278221
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Gynecol Oncol. 2019 Nov;155(2):262-269
pubmed: 31604666
Gynecol Oncol. 2011 Jun 1;121(3):615-9
pubmed: 21414656
Cell. 2018 May 3;173(4):972-988.e23
pubmed: 29656893
Clin Cancer Res. 2003 Nov 15;9(15):5721-8
pubmed: 14654557
J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):379-386
pubmed: 30936025
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Proc Natl Acad Sci U S A. 2011 Nov 1;108(44):18032-7
pubmed: 22006311
Ann Oncol. 2013 Nov;24(11):2732-9
pubmed: 23857961
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Crit Rev Oncol Hematol. 2018 Nov;131:83-89
pubmed: 30293710
Lancet Oncol. 2018 Feb;19(2):207-215
pubmed: 29361470
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Gynecol Oncol. 2017 Nov;147(2):267-275
pubmed: 28882436
J Clin Oncol. 2013 Apr 20;31(12):1554-61
pubmed: 23478059
J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45
pubmed: 16882940
Eur J Cancer. 2016 Jun;60:49-58
pubmed: 27065456
Cancer Treat Rev. 2019 Nov;80:101909
pubmed: 31629204
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Lancet Oncol. 2014 Apr;15(4):396-405
pubmed: 24582486
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
J Clin Oncol. 2009 Oct 1;27(28):4642-8
pubmed: 19704064
Cancer Treat Rev. 2018 May;66:7-14
pubmed: 29605737
Nat Rev Cancer. 2011 Dec 23;12(1):68-78
pubmed: 22193408
Gynecol Oncol. 2015 Oct;139(1):17-22
pubmed: 26216729
Gynecol Oncol. 2009 Aug;114(2):195-8
pubmed: 19447479
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Cell Cycle. 2005 Sep;4(9):1176-8
pubmed: 16123586
Mol Oncol. 2009 Apr;3(2):138-50
pubmed: 19383375
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63
pubmed: 17105988